PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-100.00%
Negative revenue growth while AXSM stands at 288.06%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
100.00%
Gross profit growth under 50% of AXSM's 294.10%. Michael Burry would be concerned about a severe competitive disadvantage.
-2.59%
Negative EBIT growth while AXSM is at 88.27%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-2.59%
Negative operating income growth while AXSM is at 88.27%. Joel Greenblatt would press for urgent turnaround measures.
-10.34%
Negative net income growth while AXSM stands at 83.20%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-10.26%
Negative EPS growth while AXSM is at 83.12%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-10.26%
Negative diluted EPS growth while AXSM is at 83.12%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.08%
Share reduction more than 1.5x AXSM's 0.18%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.08%
Diluted share reduction more than 1.5x AXSM's 0.18%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-93.84%
Negative OCF growth while AXSM is at 78.88%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-94.42%
Negative FCF growth while AXSM is at 78.76%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
81.91%
Positive long-term OCF/share growth while AXSM is negative. John Neff would see a structural advantage in sustained cash generation.
68.32%
5Y OCF/share CAGR 1.25-1.5x AXSM's 48.95%. Bruce Berkowitz would see if capital spending or working-capital efficiencies explain the difference.
41.88%
3Y OCF/share CAGR at 50-75% of AXSM's 78.70%. Martin Whitman would suspect weaker recent execution or product competitiveness.
55.55%
Net income/share CAGR above 1.5x AXSM's 5.31% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
79.95%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
56.07%
3Y net income/share CAGR 75-90% of AXSM's 70.59%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
188.20%
Below 50% of AXSM's 1090.97%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
-69.82%
Negative 5Y equity/share growth while AXSM is at 420.51%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
327.49%
3Y equity/share CAGR above 1.5x AXSM's 145.69%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.65%
Negative asset growth while AXSM invests at 17.41%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-14.02%
We have a declining book value while AXSM shows 1.88%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-4.69%
We’re deleveraging while AXSM stands at 56.02%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
7.04%
R&D dropping or stable vs. AXSM's 21.10%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-5.63%
We cut SG&A while AXSM invests at 20.64%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.